AI Article Synopsis
- The study aimed to analyze treatment utilization among men with castration-resistant prostate cancer (CRPC) in the Stockholm region between 2006 and 2016, revealing low treatment rates despite available options.
- Out of 1699 men identified, treatment rates were notably higher for progressive metastatic disease (44%) compared to others, while drugs like docetaxel (39%) and abiraterone acetate (15%) were the most commonly prescribed.
- The research also highlighted factors affecting treatment likelihood, such as age and stage at diagnosis, with treatment rates significantly increasing from 22% in 2006-2009 to 50% in 2013-2015.
Article Abstract
Background: Studies describing treatment utilization for castration-resistant prostate cancer (CRPC) are limited. We aimed to describe the treatment utilization of a contemporary population-based CRPC cohort between 2006 and 2016.
Methods: We identified 1699 men with a PC diagnosis between 2005 and 2015, who developed CRPC between 2006 and 2015 in the Stockholm region of Sweden. Demographic information, stage and grade at PC diagnosis, stage at CRPC, prostate-specific antigen (PSA) nadir, PSA doubling time, treatment utilization rate within 1 year of CRPC diagnosis, reason for stopping therapy, treatment sequence trajectory, overall and PC specific survival was described.
Results: Treatment for men with de novo metastatic disease ( = 463) was 32%, treatment for men with progressive metastatic disease after PC diagnosis ( = 66) was 44%, treatment for men with nonmetastatic CRPC ( = 113) was 34% and treatment for those with an unknown stage at time of CRPC diagnosis ( = 857) was 12%. Docetaxel was used in 39%, abiraterone acetate plus prednisone in 15%, enzalutamide in 13%, cabazitaxel in 11% and radium-223 in 5% of treatments. Treatment increased from 22% in 2006-2009 for metastatic cancer to 50% in 2013-2015 ( < .001). Factors associated with treatment were an unknown stage at diagnosis (OR: 0.3, 95% CI: 0.2-0.4), age ≥75 years (OR: 0.2, 95% CI: 0.1 - 0.3), PSA doubling time >3 months (OR: 0.4, 95% CI: 0.3 - 0.6) and a diagnosis between 2013 and 2015 (OR: 3.4, 95% CI: 2.0 - 5.8).
Conclusions: Despite treatment availability, in this large real-world cohort we found treatment utilization to remain low.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/21681805.2021.1936626 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!